Drugs moving into the clinic: 27

By Mike Nagle

- Last updated on GMT

Related tags Acute myeloid leukemia Hormone Atherosclerosis

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
SponsorNameIndication Mechanism
Orexo OX 19 (sublingual desmopressin) nocturia & urinary incontinence New formulation of Ferring Pharmaceuticals' drug that mimics the action of antidiuretic hormone, also known as arginine vasopressin. It binds to V2 receptors in renal collecting ducts, increasing water resorption, and also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor.
TopoTarget & CuraGenbelinostat (PXD101) Oncology - acute myeloid leukemia (AML)histone deacetylase inhibitor (HDAC)
Roche & Memory Pharmaceuticals R4996/MEM 63908 Alzheimer's disease, schizophrenia, plus other psychiatric and neurological disorders. partial agonist of the nicotinic alpha-7 receptor
Zydus Cadila Healthcare ZYH7 Metabolism - dyslipidemia undisclosed
BioVascular & RevitusBVI-007Cardiovascular - prevention of myocardial infarction, thrombotic stroke and death in patients who have had a previous cardiovascular eventThrombopoeitin inhibitor

Related topics Preclinical Research

Related news

Show more

Follow us


View more